Product Description
ZL-1503 is a bispecific, Serum Half-life Extended Antibody Targeting Both Inflammatory and Pruritogenic Pathways for Atopic Dermatitis and Other IL-13/IL-31 Related Diseases. (Sourced from: https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-present-preclinical-data-zl-1503-il-13il-31-bispecific)
Mechanisms of Action: IL13 Inhibitor,IL31 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zai Lab
Company Location: SHANGHAI F4 201210
Company CEO: Samantha (Ying) Du
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|